Official Title
Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome
Brief Summary

The purpose of this study is to test if senescent cells and their secretome contribute toLong-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectivelyeliminate senescent cells, should be initiated.

Detailed Description

Not Provided

Enrolling by invitation
SARS-CoV2 Infection
Eligibility Criteria

Longhauler's Cohort -

Inclusion Criteria:

- Ability to give informed consent or LAR.

- At least 18 years old.

- Ability of subject or LAR to read and speak the English language.

- Positive PCR or antibody test within 12 months of initial study visit.

- Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler
Syndrome.

Exclusion Criteria:

- Any potential participant who refuses medical record review.

- Pregnant females.

- Incarcerated individuals.

- Inability to cooperate or any medical condition that, in the opinion of the
investigator, interferes with the evaluation of the study objectives or increases
the subject's risk by participating in the study.

Control Cohort -

Inclusion Criteria:

- Ability to give informed consent

- At least 18 years old

- Ability of subject to read and speak the English language

Exclusion Criteria:

- Known case of COVID-19.

- Any potential participant who refuses medical record review.

- Pregnant females.

- Incarcerated individuals.

- Inability to cooperate or any medical condition that interferes with the evaluation
of the study objectives or increases the subject's risk by participating in the
study.

COVID-19 Control Cohort

Inclusion Criteria:

- Ability to give informed consent.

- At least 18 years old.

- Ability of subject to read and speak the English language.

- Known case of COVID-19.

Exclusion Criteria:

- Known Longhauler's syndrome/Post-COVID

- Any potential participant who refuses medical record review.

- Pregnant females.

- Incarcerated individuals.

- Inability to cooperate or any medical condition that interferes with the evaluation
of the study objectives or increases the subject's risk by participating in the
study.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Mayo Clinic in Rochester
Rochester, Minnesota, United States

James Kirkland, MD, PhD, Principal Investigator
Mayo Clinic

NCT Number
MeSH Terms
COVID-19